4D Molecular Therapeutics' Phase 2 Expansion Cohort dose selection is expected in Q2 2024 based on all clinical and lung biopsy data. Initial suspension manufacturing process completed in-house at 500 ...
4D Molecular Therapeutics reports positive interim data for 4D-150 in wet AMD and DME, with strong financial position and strategic focus. 4D Molecular Therapeutics announced positive interim data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results